NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced... Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
- Mechanism
- Curator reviewed
Raf-1 protein serine threonine kinase plays an important role in cell survival and proliferation. Antisense inhibition of Raf-1 expression by drugs such as LErafAON has been shown to enhance the cytotoxic effects of radiation and anticancer drugs.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with LErafAON, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account